Clinical Use of Cystatin C in 2026

As healthcare systems advance precision diagnostics and risk stratification, integrating Cystatin C into routine practice is increasingly important. A measure of kidney function, Cystatin C offers advantages over serum creatinine, including fewer non-GFR determinants and improved CKD diagnosis, staging, and prognosis. For most ambulatory patients, the combined creatinine and Cystatin C equation provides the most accurate estimate of GFR¹. In this webinar, Dr. Michael G. Shlipak will deliver practical, evidence-based guidance for incorporating Cystatin C testing into clinical care.

Learning Objectives:

• Understand the clinical benefits and relevance of Cystatin C testing in kidney health
• Review how CysC compares to serum creatinine (SCr)
• Explore how incorporating CysC improves CKD diagnosis, staging, and risk stratification
• Evaluate the role of combined eGFRcr-cys equations in clinical practice

Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Group viewing options are available - see our CE credit page for more information.

1.Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737-1749.
doi:10.1056/NEJMoa2102953